Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2000-01-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.97.1.365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

  1996cited by this paper
• Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes.

  1995cited by this paper
• Renal tubule cell repair following acute renal injury.

  1995cited by this paper
• Overexpression of the Human Lysosomal Enzyme α-L-Iduronidase in Chinese Hamster Ovary Cells

  1994cited by this paper
• Fabry disease: Immunocytochemical characterization of neuronal involvement

  1992cited by this paper
• Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes.

  1990cited by this paper
• The biogenesis of lysosomes.

  1989cited by this paper
• Nervous system involvement in Fabry's disease: Clinicopathological and biochemical correlation

  1988cited by this paper
• Fabry's disease: absence of storage as a feature of liver sinus endothelium.

  1985cited by this paper
• Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease.

  1984cited by this paper
• Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.

  1981cited by this paper
• High-performance liquid chromatographic analysis of neutral glycosphingolipids as their per-O-benzoyl derivatives.

  1980cited by this paper
• Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling.

  1980cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.

  1979cited by this paper
• Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

  1978cited by this paper
• Purification and properties of the two major isozymes of alpha-galactosidase from human placenta.

  1978cited by this paper
• Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives.

  1977cited by this paper
• Uptake of radiolabeled galactosyl-(α1 → 4)-galactosyl-(β1 → 4)-glucosylceramide by human serum lipoproteins in vitro

  1976cited by this paper
• Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain

  1973cited by this paper
• Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.

  1973cited by this paper
• Ultrastructure of the proximal convoluted tubules during repair following hormonally induced necrosis in rat kidney

  1973cited by this paper
• Enzyme replacement therapy by renal allotransplantation in Fabry's disease.

  1972cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Concentrations of glycosyl ceramides in plasma and red cells in Fabry's disease, a glycolipid lipidosis.

  1969cited by this paper
• Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

  1967cited by this paper
• IMPROVED PROCEDURE FOR THE EXTRACTION OF LIPIDS FROM HUMAN ERYTHROCYTES.

  1965cited by this paper

• Enzyme replacement therapy using a modified α-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic/Gla-knockout mice.

  2025cites this paper
• Use of a mouse-human chimeric anti-α-galactosidase A monoclonal antibody as a reference for measuring serum antidrug antibody titers in patients with Fabry disease.

  2024cites this paper
• The Importance of Early Treatment of Inherited Neuromuscular Conditions

  2024cites this paper
• Anderson–Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement

  2024cites this paper
• Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice

  2024influential citation
• Evaluating the Metabolic Basis of α-Gal A mRNA Therapy for Fabry Disease

  2024cites this paper
• Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies.

  2023cites this paper
• Novel enhancer mediates the RPL36A-HNRNPH2 readthrough loci and GLA gene expressions associated with fabry disease

  2023cites this paper
• Newborn Screening for Fabry Disease: Current Status of Knowledge

  2023cites this paper
• Population Frequency of Undiagnosed Fabry Disease in the General Population

  2023cites this paper
• Automated urinary sediment detection for Fabry disease using deep-learning algorithms

  2022cites this paper
• Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options

  2022cites this paper
• Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis

  2022cites this paper
• A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease

  2022influential citation
• Lysosomal storage diseases. Sphingolipidoses — Fabry, Gaucher and Farber diseases

  2022cites this paper
• A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)

  2021cites this paper
• New drugs for the treatment of Anderson–Fabry disease

  2020cites this paper
• Biomarkers in Anderson–Fabry Disease

  2020cites this paper
• Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.

  2020cites this paper
• Fabry cardiomyopathy: Gb3‐induced auto‐reactive panmyocarditis requiring heart transplantation

  2020cites this paper
• Prediction of Improved Therapeutics for Fabry Disease Patients Generated by Mutagenesis of the á-Galactosidase A Active Site, Dimer Interface, and Glycosylation Region.

  2020cites this paper
• Rare Etiology of Renal Failure in a 25-Year-Old Caucasian Man: Fabry Disease With a Novel Mutation of GLA Gene

  2020cites this paper
• Developments in the treatment of Fabry disease

  2020cites this paper
• Fabry keratopathy: manifestations and changes over time

  2019cites this paper
• Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.

  2019cites this paper
• Lysosomal storage disorders: pathology within the lysosome and beyond

  2019cites this paper
• Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease

  2019cites this paper
• Glycosylation in health and disease

  2019cites this paper
• Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)

  2019cites this paper
• Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy

  2019cites this paper
• Systematic review of oral and craniofacial findings in patients with Fabry disease or Pompe disease.

  2019cites this paper
• Import of TAT-Conjugated Propionyl Coenzyme A Carboxylase Using Models of Propionic Acidemia

  2018cites this paper
• Lysosome biogenesis in health and disease

  2018cites this paper
• Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

  2018cites this paper
• Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients

  2018cites this paper
• Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy

  2018cites this paper
• Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

  2018cites this paper
• Parapelvic cysts, a distinguishing feature of renal Fabry disease

  2018cites this paper
• Therapeutic Strategies Targeting Inherited Cardiomyopathies

  2017cites this paper
• Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy.

  2017cites this paper
• Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.

  2017cites this paper
• Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016)

  2017cites this paper
• A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome

  2016cites this paper
• A 15-Year Perspective of the Fabry Outcome Survey:

  2016cites this paper
• Mucopolysaccharidoses

  2016cites this paper
• Neurological Findings in Anderson-Fabry Disease

  2016cites this paper
• [Treatment of Fabry disease: Successes, failures, and expectations].

  2016cites this paper
• Towards the development of an enzyme replacement therapy for the metabolic disorder propionic acidemia

  2016cites this paper
• reconocimiento en la edad pediátrica

  2016cites this paper
• Fabry Outcome Survey Analyses and Publications : Highlights of the Last 15 Years Diagnosis , Disease Severity , and Mortality

  2016cites this paper
• Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice

  2015cites this paper
• Carboxyl-Terminal Truncations Alter the Activity of the Human α-Galactosidase A

  2015cites this paper
• Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment

  2015cites this paper
• Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy

  2015cites this paper
• Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

  2015cites this paper
• Systematic purification of salt‐intolerant proteins by ion‐exchange chromatography: The example of human α‐galactosidase A

  2015cites this paper
• A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease

  2015cites this paper
• Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease

  2015cites this paper
• Chapter 38 – Fabry Disease: α-Galactosidase A Deficiency

  2015cites this paper
• Innate and Adaptive Immune Response in Fabry Disease.

  2015influential citation
• Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

  2014cites this paper
• First‐in‐human study with new recombinant agalsidase beta (ISU303) in healthy subjects

  2014cites this paper
• Agalsidase alfa for the treatment of fabry disease: a closer look

  2014cites this paper
• Application of mass spectrometry in newborn screening: about both small molecular diseases and lysosomal storage diseases.

  2014cites this paper
• Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes.

  2014cites this paper
• The kidney in Fabry's disease

  2014cites this paper
• Prevalence of Fabry disease in stroke patients--a systematic review and meta-analysis.

  2014cites this paper
• Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurements

  2013cites this paper
• Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.

  2013cites this paper
• ENZYME REPLACEMENT THERAPY FOR FABRY DISEASE

  2013cites this paper
• Therapies for Lysosomal Storage Diseases

  2013cites this paper
• Fabry disease in children: agalsidase‐beta enzyme replacement therapy

  2013cites this paper
• Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.

  2013cites this paper
• Fabry Disease (α-Galactosidase A Deficiency)

  2013cites this paper
• Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa

  2013cites this paper
• Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors

  2013cites this paper
• Comparative Study of Structural Changes Caused by Different Substitutions at the Same Residue on α-Galactosidase A

  2013cites this paper
• Development of a Highly Sensitive Immuno-PCR Assay for the Measurement of α-Galactosidase A Protein Levels in Serum and Plasma

  2013cites this paper
• A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.

  2013cites this paper
• Genetic Abnormalities in Glomerular Function

  2013cites this paper
• Agalsidase Alfa

  2012cites this paper
• Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease

  2012cites this paper
• Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease

  2012cites this paper
• Mutant α-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level.

  2012cites this paper
• Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease

  2012cites this paper
• New Prospects for the Treatment of Lysosomal Storage Diseases

  2012cites this paper
• Treatment of Lysosomal Storage Disorders

  2012cites this paper
• Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy

  2012cites this paper
• Efficient Uptake of Recombinant α-Galactosidase A Produced with a Gene-Manipulated Yeast by Fabry Mice Kidneys

  2012cites this paper
• Mannose 6-Phosphate Receptor and Sortilin Mediated Endocytosis of α-Galactosidase A in Kidney Endothelial Cells

  2012cites this paper
• A meta-metabolome network of carbohydrate metabolism: interactions between gut microbiota and host.

  2012cites this paper
• Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

  2012cites this paper
• Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases

  2011cites this paper
• Fabry Disease Superimposed on Overt Autoimmune Hypothyroidism

  2011cites this paper
• Chapter 25 – Heart Failure as a Consequence of Restrictive Cardiomyopathy

  2011cites this paper
• Enzyme replacement therapy for Fabry disease: some answers but more questions

  2011cites this paper
• Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis

  2011cites this paper
• Individual organelle pH determinations of magnetically enriched endocytic organelles via laser-induced fluorescence detection.

  2011cites this paper
• Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease

  2011cites this paper
• CINÉTICA DA ENZIMA ALFA-GALACTOSIDASE A E INVESTIGAÇÃO DE DOENÇA DE FABRY EM PACIENTES HEMODIALISADOS

  2011cites this paper